Clinical Trials · NCT05822830
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 751
- Start date
- Apr 2023
- Locations
- 32 sites, United States, Puerto Rico
- Primary endpoint
- Percent Change From Baseline in Body Weight